neurology-congress-2016_scientifictracks-abstracts

9 / 29

Volume 7, Issue 4 (Suppl) J Neurol Neurophysiol
ISSN:2155-9562 JNN, an open access journal
Page 35
Notes:
Neurology Congress 2016
September 21-23, 2016
conferenceseries.com
September 21-23, 2016 Amsterdam, Netherlands
8th European Neurology Congress
Palmitoylethanolamide trial on Charcot-Marie-Tooth (CMT) neuropathy
Giovanni Antioco Putzu
Casa di Cura Polispecialistica Sant'Elena, Italy
C MT is one of the most commonly inherited neuromuscular diseases, with prevalence of approximately 1 in 2,500 persons. Clinical
complains are mainly represented by muscle pain, sensation of fatigue and painful muscle cramps. No treatment of clinical
symptoms is available yet. Previous treatment with high dosage of vitamin C failed to confirm a benefit in humans. A clinical open
trial has been performed in order to evaluate the efficacy of ultramicronized palmitoylethanolamide (PEA-um®). Twenty-two patients
(7 male and 15 females) from four different CMT families were treated with PEA-um® at dosage of 1200 mg/day for 80 days (Normast
®, Epitech Group srl, Saccolongo, Italy). None of the patients had an add-on treatment for the clinical symptoms. Muscle pain, fatigue
and muscle cramps were assessed at T0 (baseline), T1 (20th day) and T2 (80th day) using Visual Analogic Scale (VAS). Muscle strength,
vibratory sensation and Motor/Sensory nerve Conduction velocities were also assessed with the same schedule. Mean values of VAS
for muscle pain at T1 decreased from 5.9±2.1 to 3.9±1.7 (p<0.0001), whereas VAS for fatigue decreased from 6.3±2.4 to 3.4±1.6
(p<0.0001). VAS score for painful cramps at T1 diminished from 5.4±1.2 to 3.8±1.3 (p<0.0001). A further improvement of VAS scores
for muscle pain, fatigue and painful cramps was observed at T2 evaluation. These data strongly suggest that PEA-um® is effective in
improving clinical symptoms of CMT neuropathy, albeit the obvious limitation of an open study.
Biography
Giovanni Antioco Putzu is working as professor in Neurology and Clinical Neurophysiology in Casa di Cura Sant’Elena, Italy. He has published more than 40 papers
in reputed journals and has been serving as an editorial board member of reputed scientific journals.
Giovanni Antioco Putzu, J Neurol Neurophysiol 2016, 7:4 (Suppl)